Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity ... Novo attributed first-quarter obesity product revenue of 704 million Danish kroner ($110 million) in ...

Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug ... Competition is expected to ramp up in 2026 when cheaper alternative versions of ...

At first, Chinese pharmaceutical companies rushed to make similar versions of blockbuster weight-loss drugs, such as Wegovy and Ozempic, that have taken the world by storm ... risk of cardiovascular ...

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

The Health Secretary will set out a 10-year plan including proposals to bring down the cost of drugs such as Wegovy and ...

Wall Street’s major averages closed Friday's trading session higher, as both the S&P 500 (SP500) and Nasdaq Composite ...

With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough ...

India’s long-term investment case is increasingly driven by more than interest rates or global cycles. Local consumption, ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Grey market grows for cheap weight-loss drugs imported from China Some users try small doses of substances not yet approved ...